AVID BIOSERVICES INC. - COMMON STOCK

Avid Bioservices to Serve as Commercial Manufacturer for ADC Therapeutics’ ZYNLONTA™ (Loncastuximab Tesirine-Lpyl)

25 5 2021 08:05:00 提供 Nasdaq GlobeNewswire

Avid Bioservices Announces Completion of Redemption of Series E Convertible Preferred Stock

15 4 2021 16:05:00 提供 Nasdaq GlobeNewswire

Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

17 3 2021 08:05:00 提供 Nasdaq GlobeNewswire

Avid Bioservices, Inc. Announces Pricing of $125 Million Offering of Exchangeable Senior Notes

10 3 2021 00:20:03 提供 Nasdaq GlobeNewswire

Avid Bioservices, Inc. Announces Proposed $125 Million Offering of Exchangeable Senior Notes

08 3 2021 17:01:00 提供 Nasdaq GlobeNewswire

Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock

03 3 2021 16:05:00 提供 Nasdaq GlobeNewswire

Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2021 After Market Close on March 8, 2021

01 3 2021 16:05:00 提供 Nasdaq GlobeNewswire

Avid Bioservices Begins Phase 2 of its Myford Manufacturing Capacity Expansion Plan

22 2 2021 08:05:00 提供 Nasdaq GlobeNewswire

Humanigen and Avid Bioservices Enter into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing

03 2 2021 07:00:00 提供 Nasdaq GlobeNewswire